Dapagliflozin: 'No' from FDA advisers could spell trouble for new diabetes class
This article was originally published in Scrip
Executive Summary
An FDA advisory panel voted 9-6 against approving dapagliflozin, the most advanced candidate in the novel SGLT-2 inhibitor antidiabetic class. Co-developers Bristol-Myers Squibb and AstraZeneca were hoping that the drug would be the first market entrant of the novel sodium glucose co-transporter-2 (SGLT-2) inhibitor class (scripintelligence.com, 20 July 2011).